Dutrebis

RSS

lamivudine / raltegravir potassium

Table of contents

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Dutrebis has been withdrawn at the request of the marketing authorisation holder.

This EPAR was last updated on 27/04/2017

Authorisation details

Product details
Name
Dutrebis
Agency product number
EMEA/H/C/003823
Active substance
  • lamivudine
  • raltegravir potassium
International non-proprietary name (INN) or common name
lamivudine / raltegravir potassium
Therapeutic area (MeSH)
HIV Infections
Anatomical therapeutic chemical (ATC) code
J05AR16
Publication details
Marketing-authorisation holder
Merck Sharp Dohme Limited
Revision
0
Date of issue of marketing authorisation valid throughout the European Union
26/03/2015
Contact address
Hertford Road
EN11 9BU Hoddesdon
United Kingdom

Product information

26/03/2015 Dutrebis - EMEA/H/C/003823 - -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • Antivirals for systemic use

  • Antivirals for treatment of HIV infections, combinations

Therapeutic indication

Dutrebis is indicated in combination with other anti‑retroviral medicinal products for the treatment of human immunodeficiency virus (HIV‑1) infection in adults, adolescents, and children from the age of 6 years and weighing at least 30 kg without present or past evidence of viral resistance to antiviral agents of the InSTI (Integrase Strand Transfer Inhibitor) and NRTI (Nucleoside Reverse Transcriptase Inhibitor) classes (see sections 4.2, 4.4 and 5.1).

Assessment history

Initial marketing-authorisation documents

How useful was this page?

Add your rating